Financials Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Equities

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
13.31 ^CNY	+1.22%		+7.69%	-27.39%

Apr. 26	Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 11	Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug in Singapore	MT

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	12,924	15,972	12,659	13,655	15,115	10,975	-	-
Enterprise Value (EV) ¹	12,924	15,972	12,659	13,655	15,115	10,975	10,975	10,975
P/E ratio	83.5 x	38.2 x	83.5 x	43.5 x	72.1 x	23.8 x	18.9 x	-
Yield	-	-	-	0.91%	0.68%	0.56%	-	-
Capitalization / Revenue	4.32 x	4.67 x	3.24 x	3.81 x	4.61 x	2.85 x	2.57 x	-
EV / Revenue	4.32 x	4.67 x	3.24 x	3.81 x	4.61 x	2.85 x	2.57 x	-
EV / EBITDA	26.2 x	22.3 x	26.6 x	23.6 x	31.1 x	12 x	9.7 x	-
EV / FCF	-	-	-	-	-64.6 x	41.6 x	19.6 x	17.4 x
FCF Yield	-	-	-	-	-1.55%	2.41%	5.11%	5.74%
Price to Book	3.01 x	3.57 x	2.88 x	2.88 x	3.17 x	2.1 x	1.98 x	-
Nbr of stocks (in thousands)	802,214	802,214	802,214	824,596	824,596	824,596	-	-
Reference price ²	16.11	19.91	15.78	16.56	18.33	13.31	13.31	13.31
Announcement Date	2/21/20	4/29/21	4/28/22	4/28/23	4/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	2,993	3,419	3,912	3,583	3,276	3,853	4,277	-
EBITDA ¹	492.8	715.3	476.4	578.7	485.8	914.1	1,132	-
EBIT ¹	393.8	609.1	356.9	448.3	341.7	718.3	908.1	-
Operating Margin	13.16%	17.82%	9.12%	12.51%	10.43%	18.64%	21.23%	-
Earnings before Tax (EBT) ¹	395.8	611.4	356.1	445.6	337.3	717.9	907.3	-
Net income ¹	154.7	417.8	151.6	307.3	209.7	460.2	578.9	-
Net margin	5.17%	12.22%	3.87%	8.58%	6.4%	11.94%	13.54%	-
EPS ²	0.1929	0.5208	0.1889	0.3804	0.2543	0.5583	0.7040	-
Free Cash Flow ¹	-	-	-	-	-233.9	264	561.2	630
FCF margin	-	-	-	-	-7.14%	6.85%	13.12%	-
FCF Conversion (EBITDA)	-	-	-	-	-	28.88%	49.59%	-
FCF Conversion (Net income)	-	-	-	-	-	57.37%	96.94%	-
Dividend per Share ²	-	-	-	0.1500	0.1250	0.0750	-	-
Announcement Date	2/21/20	4/29/21	4/28/22	4/28/23	4/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	-	-234	264	561	630
ROE (net income / shareholders' equity)	3.65%	9.57%	3.43%	6.79%	4.53%	8.87%	10.5%	-
ROA (Net income/ Total Assets)	-	-	-	3.88%	-	5.23%	6.45%	-
Assets ¹	-	-	-	7,917	-	8,793	8,976	-
Book Value Per Share ²	5.350	5.570	5.480	5.760	5.790	6.330	6.720	-
Cash Flow per Share ²	0.8700	0.7100	1.180	1.210	0.3400	0.9900	1.070	-
Capex ¹	250	249	530	389	511	409	212	82
Capex / Sales	8.36%	7.27%	13.54%	10.86%	15.6%	10.62%	4.95%	-
Announcement Date	2/21/20	4/29/21	4/28/22	4/28/23	4/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.31 CNY

Average target price

20.3 CNY

Spread / Average Target

+52.52%

	1st Jan change	Capi.
YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD.	-27.39%	1.51B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B